Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2014

01-08-2014 | Rapid Communications

Stool Methylated DNA Markers Decrease Following Colorectal Cancer Resection—Implications for Surveillance

Authors: John B. Kisiel, Tracy C. Yab, William R. Taylor, Douglas W. Mahoney, David A. Ahlquist

Published in: Digestive Diseases and Sciences | Issue 8/2014

Login to get access

Abstract

Background

Molecular changes associated with colorectal cancer (CRC) are detected by stool deoxyribonucleic acid testing but could persist following tumor resection.

Aims

We sought to determine whether methylated gene markers in stool normalize after CRC resection.

Methods

We studied stools from 22 CRC cases before and after subtotal resection and from 80 colonoscopy-normal controls. In blinded fashion, target genes (methylated NDRG4 and BMP3) were captured from stool supernatant, bisulfite-treated, and assayed by quantitative allele-specific real-time target and signal amplification. Results were dichotomized at 95 % specificity cutoffs.

Results

Among CRC cases, median methylated NDRG4 and BMP3 levels decreased dramatically (4- to 15-fold) following resection, p = 0.003 and p < 0.0001, respectively. Among the 14 cases with elevated preoperative levels, 13 (93 %) fell into the normal range after surgery, p = 0.0002. A case whose stool methylated NDRG4 level increased sharply after surgery was found to have recurrent CRC.

Conclusions

Methylated gene marker levels clear from stool following CRC resection unless disease is present. Postoperative stool marker levels are informative and may be of value in surveillance.
Literature
1.
go back to reference Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American cancer society, the US multi-society task force on colorectal cancer, and the American college of radiology. Gastroenterology. 2008;134:1570–1595.PubMedCrossRef Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American cancer society, the US multi-society task force on colorectal cancer, and the American college of radiology. Gastroenterology. 2008;134:1570–1595.PubMedCrossRef
2.
go back to reference Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American college of gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009;104:739–750.PubMedCrossRef Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American college of gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009;104:739–750.PubMedCrossRef
3.
go back to reference Shen L, Kondo Y, Rosner GL, et al. Mgmt promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst. 2005;97:1330–1338.PubMedCrossRef Shen L, Kondo Y, Rosner GL, et al. Mgmt promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst. 2005;97:1330–1338.PubMedCrossRef
4.
go back to reference Edge SBB, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC cancer staging manual. 7th ed. New York: Springer; 2010:646. Edge SBB, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC cancer staging manual. 7th ed. New York: Springer; 2010:646.
5.
go back to reference Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American cancer society and the US multi-society task force on colorectal cancer. Gastroenterology. 2006;130:1865–1871.PubMedCrossRef Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American cancer society and the US multi-society task force on colorectal cancer. Gastroenterology. 2006;130:1865–1871.PubMedCrossRef
6.
go back to reference Lidgard GP, Domanico M, Bruinsma JJ, et al. An optimized multi-marker stool test for colorectal cancer screening: Initial clinical appraisal. Gastroenterology. 2012;142:S-770. Lidgard GP, Domanico M, Bruinsma JJ, et al. An optimized multi-marker stool test for colorectal cancer screening: Initial clinical appraisal. Gastroenterology. 2012;142:S-770.
7.
go back to reference Lidgard GP, Domanico MJ, Bruinsma JJ, et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol. 2013;11:1313–1318.PubMedCrossRef Lidgard GP, Domanico MJ, Bruinsma JJ, et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol. 2013;11:1313–1318.PubMedCrossRef
8.
go back to reference Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. New Engl J Med. 2014;370:1287–1297.PubMedCrossRef Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. New Engl J Med. 2014;370:1287–1297.PubMedCrossRef
9.
go back to reference Syngal S, Stoffel E, Chung D, et al. Detection of stool DNA mutations before and after treatment of colorectal neoplasia. Cancer. 2006;106:277–283.PubMedCrossRef Syngal S, Stoffel E, Chung D, et al. Detection of stool DNA mutations before and after treatment of colorectal neoplasia. Cancer. 2006;106:277–283.PubMedCrossRef
10.
go back to reference Zou H, Allawi H, Cao X, et al. Quantification of methylated markers with a multiplex methylation-specific technology. Clin Chem. 2012;58:375–383.PubMedCrossRef Zou H, Allawi H, Cao X, et al. Quantification of methylated markers with a multiplex methylation-specific technology. Clin Chem. 2012;58:375–383.PubMedCrossRef
11.
go back to reference Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 2012;142:248–256.PubMedCentralPubMedCrossRef Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 2012;142:248–256.PubMedCentralPubMedCrossRef
12.
go back to reference Ahlquist DA, Taylor WR, Yab TC, et al. Aberrantly methylated gene marker levels in stool: effect of demographic exposure, body mass, and other patient characteristics. J Mol Biomark Diagn. 2012;3:133. Ahlquist DA, Taylor WR, Yab TC, et al. Aberrantly methylated gene marker levels in stool: effect of demographic exposure, body mass, and other patient characteristics. J Mol Biomark Diagn. 2012;3:133.
Metadata
Title
Stool Methylated DNA Markers Decrease Following Colorectal Cancer Resection—Implications for Surveillance
Authors
John B. Kisiel
Tracy C. Yab
William R. Taylor
Douglas W. Mahoney
David A. Ahlquist
Publication date
01-08-2014
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2014
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3265-5

Other articles of this Issue 8/2014

Digestive Diseases and Sciences 8/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.